Transparency data

Non-tech summaries 2016: projects on immune disorders

Projects granted during 2016 that have a primary purpose of translational applied research - human immune disorders.

• From: Home Office
• Published: 21 December 2017

Documents

Non-technical summaries: projects granted in 2016, volume 23

PDF, 530 KB, 83 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This document outlines the projects granted under the Animals (Scientific Procedures) Act 1986 during 2016 with a primary purpose of translational applied research - human immune disorders.

The following projects were granted:

• development of hiv-1 vaccines (hiv-1 vaccine, mice, immune responses)

• autophagy in the hematopoietic system (autophagy (self-eating), leukemia, autoimmunity, ageing immunity, vaccination)

• immunity, tolerance & treatments in type 1 diabetes (immunology, type 1 diabetes, infection, autoimmunity)

• immune regulation, autoimmunity and infection (autoimmunity infection disease prognosis)

• evaluation of antibody therapy in immune models (monoclonal antibody, immune therapy, inflammation)

• coagulation proteins in inflammation and immunity (inflammation, thrombin, immunity, atheroma)

• mechanisms for immunological memory and tolerance (T cell memory, regulatory T cell, autoimmunity, allergy)

• macrophage biology in rodents and livestock (macrophage, Csf1, Csf1r)

• development of the neonatal immune system and links with disease (immune system, neonatal, disease)

• antibodies for research and clinical purposes (monoclonal antibodies)

• production of antibodies (monoclonal, polyclonal anti-sera)

• service monoclonal and polyclonal antibody production for biological & biomedical research (polyclonal and monoclonal antibody production)

• immune mechanistic models of auto-immune disease (immune, mechanistic, adoptive transfer, inflammation)

• animal models of autoimmune disease (autoimmune, disease, transplantation)

• mechanistic models of immuno-oncology (cancer, immunology)

• analysis of thymus development and function (thymus, tolerance, autoimmunity, development)

• induction, maintenance, and regulation of type 2 immunity (helminth, infection, allergy, tolerance, T cell)

• tuning the immune response in tuberculosis (tuberculosis, immune response, macrophage, zebrafish)

• non-invasive mucosal immunisation (vaccines, non-invasive, safety, efficacy, mucosal)

• regulation of autoimmunity in models of RA and SLE (rheumatoid arthritis, systemic lupus erythematosus)

• immune responses in transplantation therapies (transplantation therapy, immunology, regenerative medicine)

• testing of ES-62-based anti-inflammatory drugs (ageing; allergy; autoimmunity; drug development; parasitic worm)

• modelling and therapeutics for autoimmune disease (autoimmune disease, gene therapy, adenovirus vector, autoimmune polyglandular syndrome type 1, intrathymic injection)

• transplantation of regenerative cellular therapies (transplantation, stem cells, function, safety, immunogenicity)

Published 21 December 2017